Presse medicale (Paris, France : 1983) · 2007
[Lewy body dementia and Parkinson disease dementia].
Сравнительное исследованиеАннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meyniel Claire, Damier Philippe
Аннотация
Lewy body dementia and Parkinson disease dementia are frequent causes of degenerative dementia: 20% of the dementias in patients older than 65 years are caused by the former and nearly 80% of patients with advanced Parkinson disease develop the latter. Symptoms of Lewy body dementia include fluctuations of cognitive performance, frontal and visuospatial impairment, visual hallucinations, and parkinsonism. Parkinson disease dementia could be differentiated in two subtypes: a "subcortical" subtype, characterized by frontal impairment with apathy and dullness and a "cortical" subtype with symptoms similar to those of Lewy body dementia. Mastery of potential iatrogenic factors is important: psychotropic drugs must be prescribed at the strict minimum, and L-dopa monotherapy at the minimal dose acceptable for correcting Parkinsonian motor symptoms should be the rule. Acetylcholinesterase inhibitors may be useful in both these types of dementia: rivastigmine is approved for treating Parkinson disease dementia and clozapine for reducing hallucinations.
Предметные рубрики MeSH
AgedAntiparkinson AgentsAntipsychotic AgentsCholinesterase InhibitorsClozapineDementiaDiagnosis, DifferentialDisease ProgressionDopamine AgentsHumansIatrogenic DiseaseLevodopaLewy Body DiseaseNeuroprotective AgentsNootropic AgentsParkinson DiseaseParkinsonian DisordersPhenylcarbamatesPsychotropic DrugsRivastigmineSerotonin Antagonists